ConfX Global
InsightXOverviewReportsSector BriefingsLeadership PulseKnowledge SessionsInterviewsArticlesTools
Sector briefing · Data and analytics

Real-world evidence and data-sharing in life sciences

Federated data, consent and regulatory acceptance.

ConfX editorial7 September 20263 min readHealthcare and life sciences
Download PDF

Why it matters

Regulators and payers increasingly consider real-world data alongside clinical trials. Access to high-quality data, and the governance to share it, is becoming a competitive capability.

Real-world data comes from health records, registries, claims and devices. Its value for decisions depends on data quality, consistent definitions and governance that patients and regulators trust.

By the numbers

26 Mar 2025the European Health Data Space Regulation entered into force 1
Mar 2027Member States must have health data access bodies 1
Mar 2029most secondary-use rules apply 1

What's changing

  • The European Health Data Space creates a framework for the secondary use of health data.
  • Regulators are publishing guidance on the use of real-world evidence in decisions.
  • Federated analysis allows research without moving patient data.

How leaders are responding

  • Building partnerships with data holders under clear governance.
  • Investing in data standards and quality assessment.
  • Using privacy-enhancing technologies for analysis.

What good looks like

  • Data governance ready for requests through health data access bodies
  • Real-world evidence studies designed with regulators early
  • Privacy-preserving analysis, such as secure processing environments

What to watch

  • Implementation of the European Health Data Space.
  • Regulatory guidance on real-world evidence in submissions.
  • Federated data networks across countries.

Where to start

Assess the quality and coverage of available data sources for one research question before committing to a programme.

Questions for your leadership team

  1. Which decisions would real-world evidence support?
  2. How good is the data we can access?
  3. How do we demonstrate trustworthy governance?